Skip to main content
SpringerLink
Log in

METABOLIC DISEASE

Who knew? PPARs may act in the brain too

  • News & Views
  • Published:

From Nature Metabolism

View current issue Submit your manuscript

New research shows that a drug conjugate that links the dual PPAR𝛼/𝛾 agonist tesaglitazar to a GLP-1 receptor agonist has superior effects on weight loss and glucose metabolism compared with monotherapy in mice. The conjugate has actions in the hypothalamus that may contribute to its benefits.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1: Conjugates for the treatment of metabolic disease.

References

  1. Drucker, D. J. Cell Metab. 27, 740–756 (2018).

    Article  CAS  Google Scholar 

  2. Ahrén, B. et al. Diabetes Obes. Metab. 20, 2210–2219 (2018).

    Article  Google Scholar 

  3. Kristensen, S. L. et al. Lancet Diabetes Endocrinol. 7, 776–785 (2019).

    Article  CAS  Google Scholar 

  4. Jastreboff, A. M. et al. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa2206038 (2022).

    Article  PubMed  Google Scholar 

  5. Quarta, C. et al. Nat. Metab. https://doi.org/10.1038/s42255-022-00617-6 (2022).

    Article  Google Scholar 

  6. Kalliora, C. & Drosatos, K. J. Cardiovasc. Pharmacol. 76, 514–526 (2020).

    Article  CAS  Google Scholar 

  7. Ryan, K. K. et al. Nat. Med. 17, 623–626 (2011).

    Article  CAS  Google Scholar 

  8. Sarruf, D. A. et al. Endocrinol. 150, 707–712 (2009).

    Article  CAS  Google Scholar 

  9. Adams, J. M. et al. Diabetes 67, 1538–1548 (2018).

    Article  CAS  Google Scholar 

  10. Ludwig, M. Q. et al. Diabetes 70, 1945–1955 (2021).

    Article  CAS  Google Scholar 

  11. MacDougald, O. A. & Lane, M. D. Annu. Rev. Biochem. 64, 345–373 (1995).

    Article  CAS  Google Scholar 

  12. Tontonoz, P. & Spiegelman, B. M. Annu. Rev. Biochem. 77, 289–312 (2008).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgery, University of Michigan, Ann Arbor, MI, USA

    Randy J. Seeley

  2. AstraZeneca, Gaithersburg, MD, USA

    Christopher J. Rhodes

Authors
  1. Randy J. Seeley
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Christopher J. Rhodes
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Randy J. Seeley.

Ethics declarations

Competing interests

R.J.S. receives research support from AstraZeneca, Novo Nordisk and Fractyl. R.J.S. has served as a paid consultant for Novo Nordisk, Scohia, CinRx, ShouTi Pharma and Fractyl. R.J.S. has equity in Calibrate and Rewind. This work was supported by NIH grants to R.J.S. P01DK117821 and P30DK089503. C.J.R. is an employee of AstraZeneca and owns AstraZeneca stock.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Seeley, R.J., Rhodes, C.J. Who knew? PPARs may act in the brain too. Nat Metab 4, 965–966 (2022). https://doi.org/10.1038/s42255-022-00625-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s42255-022-00625-6

  • Springer Nature Limited

Search

Navigation